- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05614739
Uno studio su LOXO-435 in pazienti affetti da cancro con un cambiamento in un gene chiamato FGFR3 (FORAGER-1)
Uno studio multicentrico in aperto su LOXO-435 (LY3866288) nei tumori maligni solidi avanzati con alterazioni dell'FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Panoramica dello studio
Stato
Descrizione dettagliata
This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered advanced solid tumor malignancy including metastatic urothelial cancer (UC), muscle-invasive bladder cancer (MIBC), and low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC). The study will be conducted in 2 phases. Phase 1a will assess safety, tolerability, and pharmacokinetics of Vepugratinib to determine the optimal dose for further expansion. Phase 1b will include dose expansion cohorts to evaluate the efficacy and safety of Vepugratinib as monotherapy or in combinations with other medicines that treat cancer.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Numero di telefono: 1-317-615-4559
- Email: LillyTrials@Lilly.com
Backup dei contatti dello studio
- Nome: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Luoghi di studio
-
-
-
Darlinghurst, Australia, NSW 2010
- Reclutamento
- St Vincent's Hospital
-
Hunter Region, NSW, Australia, 2310
- Reclutamento
- Calvary Mater Newcastle
-
St Leonards, Australia, 2065
- Reclutamento
- GenesisCare North Shore
-
Sydney, Australia, 2109
- Reclutamento
- Macquarie University
-
-
-
-
-
Toronto, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Hospital
-
Vancouver, Canada, V5Z 1J3
- Reclutamento
- British Columbia Cancer Agency
-
-
-
-
-
Beijing, Cina, 100730
- Reclutamento
- Beijing Hospital
-
Beijing, Cina, 100142
- Reclutamento
- Beijing Cancer hospital
-
Guangdong, Cina, 510060
- Reclutamento
- Sun Yat-Sen University- Cancer Center
-
Hangzhou, Cina, 310002
- Reclutamento
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
Hangzhou, Cina, 310003
- Reclutamento
- Zhejiang Provincial People's Hospital
-
Shanghai, Cina, 200000
- Reclutamento
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Tianjin, Cina, 300060
- Reclutamento
- Tianjin Medical University Cancer Institute & Hospital
-
Xi'an, Cina, 710061
- Reclutamento
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
-
-
-
Seoul, Corea del Sud, 05505
- Reclutamento
- Asan Medical Center
-
Seoul, Corea del Sud, 03080
- Reclutamento
- Seoul National University Hospital
-
Seoul, Corea del Sud, 03722
- Reclutamento
- Severance Hospital, Yonsei University Health System
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
-
-
-
-
Bordeaux, Francia, 33076
- Reclutamento
- Institut Bergonie
-
Lyon, Francia, 69373
- Reclutamento
- Centre Leon Berard
-
Villejuif, Francia, 94805
- Reclutamento
- Institut Gustave Roussy
-
-
-
-
-
Bonn, Germania, 53127
- Non ancora reclutamento
- Universitaetsklinikum Bonn
-
München, Germania, 81675
- Reclutamento
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
-
Tübingen, Germania, 72016
- Reclutamento
- Universitaetsklinikum Tuebingen
-
-
-
-
-
Chiba, Giappone, 277-8577
- Reclutamento
- National Cancer Center Hospital East
-
Nagoya, Giappone, 464-8681
- Reclutamento
- Aichi Cancer Center Hospital
-
Tokyo, Giappone, 104-0045
- Reclutamento
- National Cancer Center Hospital
-
Tokyo, Giappone, 135-8550
- Reclutamento
- Cancer Institute Hospital of JFCR
-
-
-
-
-
Petah Tikva, Israele, 49100
- Reclutamento
- Rabin Medical Center, Beilinson Hospital
-
Tel HaShomer, Israele, 5265601
- Reclutamento
- Sheba Medical Center
-
-
-
-
-
Milan, Italia, 20132
- Reclutamento
- IRCCS Ospedale San Raffaele
-
Roma, Italia, 00168
- Reclutamento
- UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
-
-
-
-
-
Bergen, Norvegia, 5021
- Reclutamento
- Haukeland University Hospital
-
Oslo, Norvegia, 0450
- Reclutamento
- Oslo University Hospital
-
-
-
-
-
GE Rotterdam, Olanda, 3015
- Reclutamento
- Erasmus MC
-
-
-
-
-
Manchester, Regno Unito, M20 4BX
- Reclutamento
- The Christie NHS Foundation Trust
-
Sheffield, Regno Unito, S10 2SB
- Reclutamento
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Barcelona, Spagna, 08908
- Reclutamento
- Institut Catala d'Oncologia - L'Hospitalet
-
Madrid, Spagna, 28041
- Reclutamento
- Hospital Universitario 12 de Octubre
-
Madrid, Spagna, 28050
- Reclutamento
- South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
-
Madrid, Spagna, 28033
- Reclutamento
- Fundacion MD Anderson International Espana
-
Santander, Spagna, 39008
- Reclutamento
- Hospital Universitario Marques De Valdecilla
-
-
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- Reclutamento
- University of Arizona - Cancer Center
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Reclutamento
- City of Hope
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- University of California, Los Angeles (UCLA) - Division of Hematology-Oncology
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- University of California - Irvine
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- University of California (UC) Davis Comprehensive Cancer Center
-
Stanford, California, Stati Uniti, 94305
- Reclutamento
- Stanford Medicine Cancer Center
-
-
Florida
-
Orlando, Florida, Stati Uniti, 32804
- Reclutamento
- Advent Health
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University Hospital
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- The University of Chicago Medical Center (UCMC)
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Indiana University (IU) Melvin and Bren Simon Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Reclutamento
- Mary Bird Perkins Cancer Center
-
New Orleans, Louisiana, Stati Uniti, 70121
- Reclutamento
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21231-2410
- Reclutamento
- Johns Hopkins Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Barbara Ann Karmanos Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63108
- Reclutamento
- Washington University in St. Louis
-
-
New York
-
New York, New York, Stati Uniti, 10021
- Reclutamento
- Weill Cornell Medicine
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- Columbia University
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- New York University (NYU)
-
Rochester, New York, Stati Uniti, 14642
- Reclutamento
- University of Rochester - Wilmot Cancer Institute
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Montefiore Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- University of North Carolina (UNC) - Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45267
- Reclutamento
- University of Cincinnati Medical Center (UCMC)
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University (OSU)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma - Health Sciences Center
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Stati Uniti, 17601
- Reclutamento
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- University of Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Reclutamento
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- Reclutamento
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Reclutamento
- Allegheny General Hospital
-
-
South Carolina
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Reclutamento
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tennessee Oncology
-
Nashville, Tennessee, Stati Uniti, 37212
- Reclutamento
- Vanderbilt University Medical Center
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Sarah Cannon and HCA Research Institute
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75244
- Reclutamento
- University of Texas Southwestern
-
Dallas, Texas, Stati Uniti, 75251
- Reclutamento
- Texas Oncology, P.A
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84132
- Reclutamento
- University of Utah
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05401
- Reclutamento
- University of Vermont Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Cohort A1, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy with a qualifying FGFR3 alteration.
-
Cohort A2, B2, B5 and B7: Urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration.
-
Cohorts B1 and B4: Urothelial cancer that is locally advanced or metastatic and have received prior erdafitinib.
-
Cohort B6: Muscle Invasive Bladder Cancer with a qualifying FGFR3 alteration.
-
Cohort B7: Urothelial cancer that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration and expression of human epidermal growth factor receptor 2 (HER2).
-
Cohort B8: Low Grade Intermediate Risk Non-Muscle Invasive Bladder cancer and a qualifying FGFR3 genetic alteration.
-
Measurability of disease:
- Cohort A1, D1, and D2: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1).
- Cohorts A2, B1, B2, B4, B5, B7, and C1: Measurable disease required as defined by RECIST v1.1.
- Cohort B8: Baseline disease which includes at least 1 lesion.
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status of:
- 0 or 1 for Cohorts A1, A2, B5, B6, B7, and B8.
- Less than or equal to 2 for Cohorts B1, B2, B4, C1, DI and D2.
-
Cohort B6: Must be eligible for radical cystectomy plus pelvic lymph node dissection and agree to undergo curative intent standard radical cystectomy plus pelvic lymph node dissection.
Exclusion Criteria:
-
Participants with primary central nervous system (CNS) malignancy.
-
Untreated or uncontrolled CNS metastases.
-
Current evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible.
-
Any serious unresolved toxicities from prior therapy.
-
Significant cardiovascular disease.
-
Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF).
-
Active uncontrolled systemic infection or other clinically significant medical conditions.
-
Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.
-
Cohort D1 only:
- Have had renal transplantation.
- Have a known history of nephrotic syndrome.
- Have uncontrolled fluid overload, including clinically significant ascites, pleural effusion, or peripheral edema.
- Have uncontrolled hypertension.
- Are on hemodialysis or similar.
-
Cohort D2 only:
- Have a history of:
- Ventricular tachycardia or ventricular fibrillation.
- Hypertrophic obstructive cardiomyopathy unless managed concurrently with atrial fibrillation.
- Wolff-Parkinson-White syndrome.
- Second- or third-degree atrioventricular block unless a functioning pacemaker is in place.
- Heart rate less than (<) 50 bpm.
- Have any of these medical conditions:
- Severe respiratory insufficiency.
- Sleep apnea syndrome.
- Myasthenia gravis.
- Acute narrow-angle glaucoma.
- Active liver disease or clinically significant hepatic impairment.
- History of myopathy or rhabdomyolysis with any HMG-CoA reductase inhibitor.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation
Vepugratinib administered orally |
Oral
Altri nomi:
|
|
Sperimentale: Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization
Vepugratinib administered orally |
Oral
Altri nomi:
|
|
Sperimentale: Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion
Vepugratinib administered orally |
Oral
Altri nomi:
|
|
Sperimentale: Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin
Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV |
IV Oral
Altri nomi:
IV |
|
Sperimentale: Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin
Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV |
IV Oral
Altri nomi:
IV |
|
Sperimentale: Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan
Vepugratinib administered orally in combination with trastuzumab deruxtecan administered IV |
Oral
Altri nomi:
IV |
|
Sperimentale: Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion
Vepugratinib administered orally |
Oral
Altri nomi:
|
|
Sperimentale: Phase 1b: Cohort D2 (Drug to Drug Interaction)
Vepugratinib Plus Midazolam Plus Digoxin Plus Rosuvastatin (Lead-In Only) followed by Vepugratinib Monotherapy Vepugratinib administered orally Midazolam with digoxin with rosuvastatin administered orally once per cycle for 2 cycles. |
Oral
Altri nomi:
Oral Oral Oral |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Overall Response Rate (ORR)
Lasso di tempo: Up to Approximately 30 Months or 2.5 Years
|
Up to Approximately 30 Months or 2.5 Years
|
|
Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)
Lasso di tempo: Up to 2 Months
|
Up to 2 Months
|
|
PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])
Lasso di tempo: Up to 2 Months
|
Up to 2 Months
|
|
Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)
Lasso di tempo: Up to approximately 24 months or 5 years
|
Up to approximately 24 months or 5 years
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change from Baseline in Bladder-Related Symptoms, Measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) Subscale (BlCS)
Lasso di tempo: Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
|
Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
|
|
Change from Baseline in Physical Function, Measured by FACT- Physical Well-Being Scale (PWB) Subscale
Lasso di tempo: Up to Approximately 30 Months or 2.5 Years
|
Up to Approximately 30 Months or 2.5 Years
|
|
Event-Free Survival (EFS) in Participants with Muscle Invasive Bladder Cancer (MIBC)
Lasso di tempo: Up to approximately 30 months or 2.5 years
|
Up to approximately 30 months or 2.5 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Processi neoplastici
- Malattie dell'uretere
- Carcinoma
- Malattie della vescica urinaria
- Condizioni patologiche, segni e sintomi
- Neoplasie vescicali non muscolo invasive
- Neoplasie ureterali
- Metastasi neoplastica
- Neoplasie della vescica urinaria
- Neoplasie urologiche
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Carboidrati
- Composti policiclici
- Glicosidi
- Amides
- Pirimidine
- Steroidi
- Composti anelli fusi
- Idrocarburi, alogenati
- Benzazepine
- Sulfonamidi
- Solfoni
- Benzodiazepine
- Fluorobenzenes
- Idrocarburi, fluorurati
- Digitalis Glycosides
- Cardenolides
- Glicosidi cardiaci
- Cardanolidi
- Rosuvastatina Calcio
- Midazolam
- Digossina
- pembrolizumab
- enfortumab vedotin
- trastuzumab deruxtecan
Altri numeri di identificazione dello studio
- 18594
- LOXO-FG3-22001 (Altro identificatore: Eli Lilly and Company)
- J4G-OX-JZVA (Altro identificatore: Eli Lilly and Company)
- 2022-502755-59-00 (Altro identificatore: EU CTR #)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .